Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + leucovorin + methotrexate + procarbazine

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral, Intramuscular, Intrathecal

Overview

This is a combination chemotherapy regimen containing multiple anticancer agents. Cyclophosphamide is an alkylating agent that damages DNA by binding to it and causing cross-links. Doxorubicin (also known as Adriamycin) is an anthracycline antibiotic that damages DNA by inserting itself between DNA bases. Leucovorin is a reduced form of folate that can help protect normal cells from methotrexate toxicity. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, preventing DNA synthesis. Procarbazine is an alkylating agent that can cross the blood-brain barrier.

Targets

ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TS (Thymidylate synthase)DNADHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + leucovorin + methotrexate + procarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + leucovorin + methotrexate + procarbazine.

Explore the full profile